Inhibition of discoidin domain receptor (DDR)‑1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer’s disease – May 2023
View PDF
Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies – May 2022
View PDF
CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease – December 2021
View PDF
Long-Term Safety and Clinical Effects of Nilotinib in Parkinson’s Disease – November 2020
View PDF
Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer’s Disease – May 2020
View PDF
Towards a biomarker system that supports disease modifying therapies in Parkinson’s disease – March 2020
View PDF
Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease – December 2019
View PDF
Multikinase Abl/DDR/Src Inhibition Produces Optimal Efects for Tyrosine Kinase Inhibition in Neurodegeneration – June 2019
View PDF
Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson’s disease – March 2019
View PDF
Tau clearance improves astrocytic function and brain glutamate-glutamine cycle – August 2018
View PDF
Activating Autophagy as a Therapeutic Strategy for Parkinson’s Disease – January 2018
View PDF
Discoidin domain receptor inhibition reduces neuropathology and attenuates inflammation in neurodegeneration models – October 2017
View PDF
Could cancer drugs be repurposed for use in Parkinson’s and Alzheimer’s? – December 2016
View PDF
Tyrosine kinase inhibition reverses TDP-43 effects on synaptic protein expression, astrocytic function and amino acid dis-homeostasis. – November 2016
View PDF
Nilotinib Effects in Parkinson’s Disease and Dementia with Lewy Bodies – July 2016
View PDF
Two sides of the same coin: tyrosine kinase inhibition in cancer and neurodegeneration – November 2015
View PDF
Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer’s disease models – July 2015
View PDF
Tau deletion impairs intracellular β-amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models – November 2014
View PDF
Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in αSynucleinopathy – September 2014
View PDF
Parkin-mediated reduction of nuclear and soluble TDP-43 reverses behavioral decline in symptomatic mice – September 2014
View PDF
Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance – December 2013
View PDF
Ubiquitination Increases Parkin Activity to Promote Autophagic a-Synuclein Clearance – December 2013
View PDF
Tyrosine kinase inhibition facilitates autophagic SNCA/α-synuclein clearance – August 2013
View PDF
Tyrosine kinase inhibition increases functional parkin‐Beclin‐1 interaction and enhances amyloid clearance and cognitive performance – August 2013
View PDF
Nilotinib reverses loss of dopamine neurons and improvesmotor behavior via autophagic degradation of a-synuclein in Parkinson’s disease models – May 2013
View PDF
Decreased parkin solubility is associated with impairment of autophagy in the nigrostriatum of sporadic Parkinson’s disease – December 2012
View PDF